Genotype-phenotype correlations in 5-fluorouracil metabolism: A candidate DPYD haplotype to improve toxicity prediction

Pharmacogenomics Journal

Volumn 16, Issue 4, 2016, Pages 320-325

  Gentile, G ^a,b   Botticelli, A ^b   Lionetto, L ^b   Mazzuca, F ^b,c   Simmaco, M ^a,b   Marchetti, P ^b,c   Borro, M ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GUANINE; THYMINE; ANTINEOPLASTIC ANTIMETABOLITE;

ADULT; AGED; ALLELE; ARTICLE; BILIARY TRACT CANCER; COLON CANCER; CONTROLLED STUDY; DPYD GENE; DRUG BLOOD LEVEL; DRUG DEGRADATION; ESOPHAGUS CANCER; FEMALE; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PANCREAS CANCER; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECTUM CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; ADVERSE DRUG REACTION; DRUG INACTIVATION; ENZYMOLOGY; GENE FREQUENCY; GENETIC ASSOCIATION STUDY; GENETICS; METABOLISM; MIDDLE AGED; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PHENOTYPE; RISK FACTOR;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; INACTIVATION, METABOLIC; MALE; MIDDLE AGED; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84938387725     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2015.56     Document Type: Article

References (25)

1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-338
2. Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 1988; 81: 47-51
3. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer 1991; 68: 499-501
4. Lyss AP, Lilenbaum RC, Harries BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Invest 1993; 11: 239-240
5. van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharmacogenom J 2013; 13: 389-395
6. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. German 5-FU Toxicity Study Group. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-2138
7. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-Time cellular analysis and in vitro measurement of enzyme activity. Cancer Res 2013; 73: 1958-1968
8. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res 2014; 74: 2545-2554
9. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94: 640-645
10. Cross DS, Ivacic LC, Stefanski EL, McCarty CA. Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project. BMC Genet 2010; 11: 51
11. Lee AM, Diasio RB. Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. J Clin Oncol 2014; 32: 989-990
12. Lostia AM, Lionetto L, Ialongo C, Gentile G, Viterbo A, Malaguti P, et al. A liquid chromatography-Tandem mass spectrometry method for the determination of 5-fluorouracil degradation rate by intact peripheral blood mononuclear cells. Ther Drug Monit 2009; 31: 482-488
13. SNPStats software http://bioinfo.iconcologia.net/SNPstats Last accessed 11 November 2014
14. Solé X, Guinó E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics 2006; 22: 1928-1929
15. Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-Analysis. J Clin Oncol 2014; 32: 1031-1039
16. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895-2904
17. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-Associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 2000; 6: 4705-4712
18. Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat 2003; 22: 498
19. Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011; 17: 3455-3468
20. Baskin Y, Amirfallah A, Unal OU, Calibasi G, Oztop I. Dihydropyrimidine dehydrogenase 85T4C mutation is associated with ocular toxicity of 5-fluorouracil: a case report. Am J Ther 2015; 22: e36-e39
21. Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS One 2008; 3: e4003
22. van Kuilenburg AB, Häusler P, Schalhorn A, Tanck MW, Proost JH, Terborg C, et al. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G4A mutation in DPYD by means of a Bayesian limited sampling strategy. Clin Pharmacokinet 2012; 51: 163-174
23. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996; 98: 610-615
24. Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of African ancestry associated with reduced DPD enzyme activity. Clin Pharmacol Ther 2013; 94: 158-166
25. Kouwaki M, Hamajima N, Sumi S, Nonaka M, Sasaki M, Dobashi K, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998; 4: 2999-3004